LON:CLIN

Clinigen Group Share Forecast, Price & News

GBX 602

-1.50 (-0.25 %)

(As of 10/30/2020 05:35 PM ET)

Add

Compare

Today's Range

587

Now: GBX 602▼

606

50-Day Range

570

MA: GBX 638.54▼

710

52-Week Range

350.40

Now: GBX 602▼

1,000

Volume178,852 shs

Average Volume455,278 shs

Market Capitalization£800.83 million

P/E Ratio59.02

Dividend Yield1.34%

BetaN/A

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Clinigen Group has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 997.50, Clinigen Group has a forecasted upside of 65.7% from its current price of GBX 602.
Amount of Analyst Coverage
Clinigen Group has only been the subject of 2 research reports in the past 90 days.

3.9 Community Rank

Outperform Votes
Clinigen Group has received 423 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Clinigen Group has received 118 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Clinigen Group has received 78.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote “Outperform” if you believe CLIN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Clinigen Group has a dividend yield of 1.34%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Clinigen Group does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Clinigen Group is 78.43%. Payout ratios above 75% are not desirable because they may not be sustainable.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Clinigen Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought £12,080 in company stock and sold GBX 0 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Clinigen Group is 59.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.27.
Price to Earnings Ratio vs. Sector
The P/E ratio of Clinigen Group is 59.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.33.
Price to Book Value per Share Ratio
Clinigen Group has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.03 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Delivery

Sub-IndustryN/A

SectorMedical

Current SymbolLON:CLIN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.clinigengroup.com

Phone+44-1283-495010

Employees849

Debt

Debt-to-Equity Ratio102.11

Current Ratio1.54

Quick Ratio1.24

Price-To-Earnings

Trailing P/E Ratio59.02

Forward P/E Ratio0.23

P/E GrowthN/A

Sales & Book Value

Annual Sales£504.30 million

Price / Sales1.59

Cash FlowGBX 107.09 per share

Price / Cash Flow5.62

Book ValueGBX 335.50 per share

Price / Book1.79

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares133,029,000

Market Cap£800.83 million

Next Earnings DateN/A

OptionableNot Optionable

GBX 602

-1.50 (-0.25 %)

(As of 10/30/2020 05:35 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CLIN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter.

Clinigen Group (LON:CLIN) Frequently Asked Questions

How has Clinigen Group's stock been impacted by COVID-19 (Coronavirus)?

Clinigen Group's stock was trading at GBX 657 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLIN shares have decreased by 8.4% and is now trading at GBX 602.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Clinigen Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Clinigen Group.

How were Clinigen Group's earnings last quarter?

Clinigen Group PLC (LON:CLIN) announced its quarterly earnings data on Thursday, September, 17th. The company reported $65.60 earnings per share for the quarter, beating the Zacks' consensus estimate of $63.50 by $2.10.
View Clinigen Group's earnings history.

How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?

Clinigen Group declared a dividend on Thursday, September 17th. Shareholders of record on Thursday, November 5th will be paid a dividend of GBX 5.46 per share on Wednesday, December 2nd. This represents a dividend yield of 0.85%. The ex-dividend date is Thursday, November 5th. This is an increase from Clinigen Group's previous dividend of GBX 2.15. The official announcement can be accessed at this link.
View Clinigen Group's dividend history.

What price target have analysts set for CLIN?

4 brokers have issued 1 year target prices for Clinigen Group's stock. Their forecasts range from GBX 820 to GBX 1,300. On average, they anticipate Clinigen Group's stock price to reach GBX 997.50 in the next year. This suggests a possible upside of 65.7% from the stock's current price.
View analysts' price targets for Clinigen Group.

Who are some of Clinigen Group's key competitors?

Some companies that are related to Clinigen Group include Evotec (EVT), 1life Healthcare (ONEM), PTC Therapeutics (PTCT), ConvaTec Group (CTEC), FibroGen (FGEN), Dechra Pharmaceuticals PLC (DPH.L) (DPH), SmileDirectClub (SDC), bluebird bio (BLUE), Twist Bioscience (TWST), Legend Biotech (LEGN), Insmed (INSM), Relay Therapeutics (RLAY), Principia Biopharma (PRNB), STAAR Surgical (STAA) and ChemoCentryx (CCXI).
View all competitors.

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Applicatio (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), 228608 (RTI), General Electric (GE) and NetApp (NTAP).

Who are Clinigen Group's key executives?

Clinigen Group's management team includes the following people:

Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)
Mr. Nicholas Keher, CFO & Director
Ms. Debra Ainge, Chief Operating Officer
Matt Parrish, Head of Investor Relations
Mr. David Bryant, Director of Corp. Devel.

What is Clinigen Group's stock symbol?

Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How do I buy shares of Clinigen Group?

Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Clinigen Group's stock price today?

One share of CLIN stock can currently be purchased for approximately GBX 602.

How big of a company is Clinigen Group?

Clinigen Group has a market capitalization of £800.83 million and generates £504.30 million in revenue each year. Clinigen Group employs 849 workers across the globe.

What is Clinigen Group's official website?

The official website for Clinigen Group is www.clinigengroup.com.

How can I contact Clinigen Group?

Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings